Navigation Links
Sundia Appoints Charles D. Maher as Senior Vice President of Sales and Marketing

SHANGHAI, Oct. 15 /PRNewswire-Asia/ -- Sundia MediTech, a leading pharmaceutical R&D outsourcing service company in China, announced today that Mr. Charles D. Maher has been appointed Senior Vice President of Sales and Marketing of Sundia.

Prior to joining Sundia, Mr. Maher was Executive Vice President of Global Sales and Marketing of Azopharma Product Development Group, a CRO company in Florida, USA. Azopharma's CRO service scope covers chemical synthesis, analytical, API, preclinical and clinical operations. Mr. Maher was responsible for development and execution of worldwide strategies, and the recruiting and training of business development managers and directors. Mr. Maher previously also worked for Proceryon Biosciences, a CRO company in New York, as Senior Vice President of Business Development for ten years, and for Bio-Rad Laboratories in USA as Director of Sales for eight years.

Mr. Maher has extensive experience in leading many aspects of CRO industry operations, and has accumulated a consistent track record of improving bottom line by growing revenue, reducing costs and maximizing employee productivity through his career.

In his new role in Sundia, Mr. Maher will be responsible for Sundia's business development in global market. Mr. Maher will report directly to Dr. Xiaochuan Wang, Chairman and CEO of Sundia.

"Mr. Maher's past experience is a perfect match to Sundia's business needs. I am very pleased to welcome him to join our team at this very important point of Sundia's development," commented Dr. Xiaochuan Wang. "With the rapid growth of Sundia, we need more experienced and high quality leaders in the company. I have full confidence that our business development team will deliver a outstanding result under the leadership of Mr. Maher."

Mr. Maher had his college education in Miami University with a double major in marketing management and chemistry, and obtained his MBA degree from Ohio State University in USA.

About Sundia MediTech

Sundia MediTech Company is a leading integrated pharmaceutical contract research organization (CRO) based in Shanghai, China. It was founded in Shanghai in 2004 by a group of U.S. pharmaceutical industry veterans to provide R&D outsourcing services to biotech and pharmaceutical companies worldwide.

SOURCE Sundia MediTech Company

SOURCE Sundia MediTech Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
2. Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
3. Sundia MediTech in Deloitte Technology Fast 500 Asia Pacific List
4. Sundias Animal Facility Passed Client and Government Inspection
5. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
6. Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry
7. Bioinformatics Expert Dr. Jiaan Yang Joins Sundia MediTech With Innovative PFSC Technology
8. Sundia in Top 100 Fast-growth Outsourcing Companies in China
9. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
10. Sundia Welcomes Professional U.S. Delegation
11. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
Post Your Comments:
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
Breaking Biology Technology:
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
(Date:10/27/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leader ... adopted the Synaptics ® ClearPad ® Series ... newest flagship smartphones, the Nexus 5X by LG and ... --> --> Synaptics works closely with ... in the joint development of next generation technologies. Together, ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):